Exploring JAK Inhibitors for Inflammatory Skin Disorders: Improving Outcomes for Atopic Dermatitis

Target Audience
This initiative is intended for US dermatology allied HCPs, including PAs, NPs, and nurses, as well as other allied HCPs who may be involved in the management of patients with AD.

Program Overview
Review of the clinical manifestations and assessment of Alopecia dermatitis(AD), along with clinical trial results with oral JAK inhibitors, which are showing promise. This program has been created for US dermatology allied healthcare professionals (HCPs) and will include several interactive case study discussions.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Describe the burden of AD, including clinical manifestations, associated disorders, and psychosocial impact
Describe the epidemiology of AD and disease risk factors
Describe the role of specific immunological pathways, such as JAK/STAT, in the pathogenesis of AD
Differentiate the mechanisms of emerging systemic therapies for AD, including JAK inhibitors
Evaluate the benefits and risks of JAK inhibitors and other emerging therapy classes in AD
Discuss clinical considerations associated with the potential implementation of emerging AD therapies into practice